Evolocumab公司
可欣
PCSK9
前蛋白转化酶
阿利罗库单抗
医学
脂蛋白(a)
脂蛋白
内科学
载脂蛋白B
低密度脂蛋白受体
动脉粥样硬化性心血管疾病
内分泌学
疾病
药理学
胆固醇
载脂蛋白A1
作者
Michael B. Boffa,Marlys L. Koschinsky
标识
DOI:10.1097/mol.0000000000000641
摘要
Purpose of review Evidence continues to mount for elevated lipoprotein(a) [Lp(a)] as a prevalent, independent, and causal risk factor for atherosclerotic cardiovascular disease. However, the effects of existing lipid-lowering therapies on Lp(a) are comparatively modest and are not specific to Lp(a). Consequently, evidence that Lp(a)-lowering confers a cardiovascular benefit is lacking. Large-scale cardiovascular outcome trials (CVOTs) of inhibitory mAbs targeting proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) may address this issue. Recent findings Although the ability of PCSK9i to lower Lp(a) by 15–30% is now clear, the mechanisms involved continue to be debated, with in-vitro and in-vivo studies showing effects on Lp(a) clearance (through the LDL receptor or other receptors) and Lp(a)/apolipoprotein(a) biosynthesis in hepatocytes. The FOURIER CVOT showed that patients with higher baseline levels of Lp(a) derived greater benefit from evolocumab and those with the lowest combined achieved Lp(a) and LDL-cholesterol (LDL-C) had the lowest event rate. Meta-analysis of ten phase 3 trials of alirocumab came to qualitatively similar conclusions concerning achieved Lp(a) levels, although an effect independent of LDL-C lowering could not be demonstrated. Summary Although it is not possible to conclude that PCSK9i specifically lower Lp(a)-attributable risk, patients with elevated Lp(a) could derive incremental benefit from PCSK9i therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI